543635 and PPLPHARMA Related Headlines
Go Back- Piramal Pharma acquires majority stake in Yapan Bio for $7.95M
- Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
- Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
- Piramal Pharma Limited Announces Results for Q1 FY27
- Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
- Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
- Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
- Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
- Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26
543635 and PPLPHARMA Related Press Releases
Go Back- Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
- Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
- Piramal Pharma Limited Announces Results for Q1 FY27
- Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
- Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
- Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
- Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
- Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26

